Slides and webcasts from ESMO Virtual Plenaries are open to all, ESMO Members and free ESMO Account holders, according to the presenters' agreement to release them.
Please login to see our free content!
ESMO Virtual Plenary: March 2022
- Start date
- 16 Mar 2022
- End date
- 18 Mar 2022
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Wednesday, 16 March 2022 |
Thursday, 17 March 2022 |
---|---|
18:30-19:30 CET |
13:00-14:10 CET / 20:00-21:10 SGT |
Programme
Welcome and introduction, Scientific background and context Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer Critical analysis and perspectives Live Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: webcast of 16 March OlympiA presentation + Live Discussion and Q&A (ii) Chair: Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore Andrew Tutt, The Institute of Cancer Research, London, UK Mark Robson, MSKCC - Memorial Sloan Kettering Cancer Center, New York, NY, USA Nadia Harbeck, LMU Klinikum der Universität München, Munich, Germany Ava Kwong, The University of Hong Kong, Hong Kong, China Kelly-Anne Phillips, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia |
Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Thursday, 17 March 2022 |
Friday, 18 March 2022 |
---|---|
18:00-19:00 CET |
11:45-12:55 CET / 18:45-19:55 SGT |
Programme
Welcome and introduction, Scientific background and context Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer Critical analysis and perspectives Live Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: webcast of 17 March SIENDO presentation + Live Discussion and Q&A (ii) Chair: Clare Scott, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Ignace Vergote, Leuven University Hospitals, Leuven, Belgium Amit Oza, Princess Margaret Cancer Centre, Toronto, ON, Canada Sudeep Gupta, Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, India Byoung-Gie Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea |
Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Thursday, 17 March 2022 |
Friday, 18 March 2022 |
---|---|
19:15-20:15 CET |
13:15-14:25 CET / 20:15 - 21:25 SGT |
Programme
Welcome and introduction, Scientific background and context Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study Critical analysis and perspectives Live Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: webcast of 17 March PEARLS/KEYNOTE-091 presentation + Live Discussion and Q&A (ii) Chair: Ben Solomon, Peter MacCallum Cancer Center, Melbourne, VIC, Australia Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain Martin Reck, Lungen Clinic Grosshansdorf, Grosshansdorf, Germany Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Yi-Long Wu, Guangdong Province People's Hospital, Guangzhou, China |